cytarabine has been researched along with rg7388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assouline, S; Blotner, S; Chen, LC; Dickinson, MJ; Drummond, MW; Higgins, B; Jukofsky, L; Kasner, M; Kelly, KR; Lee, JH; Martinelli, G; Monnet, A; Muehlbauer, S; Nichols, G; Ott, M; Papayannidis, C; Pierceall, WE; Seiter, K; Simon, S; Vey, N; Yee, K; Yoon, SS; Zhi, J | 1 |
| Beckermann, BM; Catalani, O; Cavenagh, J; Deeren, D; Fenaux, P; Genevray, M; Girshova, L; Jamois, C; Konopleva, MY; Krauter, J; Martinelli, G; Montesinos, P; Muehlbauer, S; Mundt, K; Ott, M; Ottmann, O; Petrini, M; Pigneux, A; Rambaldi, A; Recher, C; Rodriguez-Veiga, R; Röllig, C; Schäfer, JA; Taussig, D; Vey, N; Wei, AH; Yoon, SS | 1 |
2 trial(s) available for cytarabine and rg7388
| Article | Year |
|---|---|
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; para-Aminobenzoates; Prognosis; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Remission Induction; Tissue Distribution; Young Adult | 2021 |
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia, Myeloid, Acute; para-Aminobenzoates; Pyrrolidines | 2022 |